Quietus
(Gefapixant)Phase 3Small molecule
Merck & Co.Gefapixant is used to treat chronic cough that persists for weeks or months without a known cause. It works by blocking a pain receptor in the throat that triggers the cough reflex.[1] Quietus is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Quietus is one of 12 small molecule programs targeting Chronic Cough. It is currently in Phase 3.
1
Indications
26
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Cough
#DrugCompanyPhaseTrials
1Singulair
OOrganon and Co
Approved
Nucala
GGlaxo Dba Glaxosmithkline
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Quietus
Merck & Co.Phase 3
Pulmicort
SSalix
Preclinical
NOC-110
NNocion Therapeutics
Phase 2
HS-10383
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 2
Iron Sulphate
PPierre Fabre Pharma GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Cough12 trials
Show 9 more trials
Idiopathic Pulmonary Fibrosis2 trials
Tics2 trials
Asthma1 trial
8 more indications
Stress urinary incontinence1 trial
Osteoarthritis1 trial
Obstructive Sleep Apnea1 trial
Renal insufficiency1 trial
Endometriosis1 trial
Respiratory tract infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gefapixant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- P2X Purinoceptor 3 Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company